

PHARMACY POLICY STATEMENT

Marketplace

DRUG NAME	Ultomiris (ravulizumab-cwvz)
BILLING CODE	J1303
BENEFIT TYPE	Medical
SITE OF SERVICE ALLOWED	Home/Office/Outpatient
COVERAGE REQUIREMENTS	Prior Authorization Required (Preferred Product) QUANTITY LIMIT— see Dosage allowed
LIST OF DIAGNOSES CONSIDERED NOT MEDICALLY NECESSARY	Click Here

Ultomiris (ravulizumab-cwvz) is a **preferred** product and will only be considered for coverage under the **medical** benefit when the following criteria are met:

Members must be clinically diagnosed with one of the following disease states and meet their individual criteria as stated.

ATYPICAL HEMOLYTIC UREMIC SYNDROME (aHUS)

For **initial** authorization:

1. Medication is prescribed by or in consultation with a hematologist or nephrologist; AND
2. Member has a diagnosis of aHUS supported by ALL of the following:
 - a) Thrombocytopenia (platelet count < 150 x 10⁹/L),
 - b) Evidence of hemolysis i.e. elevated lactate dehydrogenase (LDH), low haptoglobin count, or presence of fragmented red blood cells or schistocytes on blood smear,
 - c) Evidence of renal impairment (e.g. raised SCr or low eGFR); AND
3. Shiga toxin-producing E. coli related HUS (STEC-HUS) has been ruled out; AND
4. ADAMTS13 activity level is > 5% (to rule out TTP); AND
5. Member has received meningococcal vaccine.
6. **Dosage allowed:** Administered by IV infusion; loading dose followed by maintenance doses starting 2 weeks later, based on body weight, per prescribing information. See appendix at end of policy.

If member meets all the requirements listed above, the medication will be approved for 6 months.

For **reauthorization**:

1. Chart notes must demonstrate hematologic normalization as evidenced by increased platelet count or LDH maintained below upper limit of normal; AND
2. Improved or preserved kidney function.

If member meets all the reauthorization requirements above, the medication will be approved for an additional 12 months.

PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)

For **initial** authorization:

1. Medication is prescribed by or in consultation with a hematologist; AND
2. Member has a diagnosis of PNH as confirmed by flow cytometry; AND
3. Member has a lactate dehydrogenase (LDH) level >1.5x upper limit of normal (ULN); AND
4. Member has received meningococcal vaccine.
5. **Dosage allowed:** Administered by IV infusion; loading dose followed by maintenance doses starting 2 weeks later, based on body weight, per prescribing information. See appendix at end of policy.

If member meets all the requirements listed above, the medication will be approved for 6 months.

For **reauthorization**:

1. Clinical evidence of positive response to therapy such as increased hemoglobin level, decreased need for transfusions, normalized LDH levels, improved fatigue.

If member meets all the reauthorization requirements above, the medication will be approved for an additional 12 months.

CareSource considers Ultomiris (ravulizumab-cwvz) not medically necessary for the treatment of diseases that are not listed in this document.

DATE	ACTION/DESCRIPTION
05/07/2019	New policy for Ultomiris created.
10/26/2019	New diagnosis of aHUS added.
06/03/2021	aHUS: Updated references. Added specialist requirement. Revised diagnostic parameters. Summarized excluded causes. Removed list of restrictions from clinical trials. Revised renewal criteria. PNH: Updated references. Removed nephrology as specialist. Removed transfusion and organ damage requirements. Updated dosing information. Reduced initial approval duration from 12 months to 6 months. Revised renewal criteria.

References:

1. Ultomiris [package insert]. Boston, MA: Alexion Pharmaceuticals, Inc., June 2021.
2. Kaplan BS, Ruebner RL, Spinale JM, Copelovitch L. Current treatment of atypical hemolytic uremic syndrome. *Intractable Rare Dis Res.* 2014;3(2):34-35. Doi: 10.5582/irdr.2014.01001.
3. Tanaka K, Adams B, Aris AM, et al. The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab [published correction appears in *Pediatr Nephrol.* 2020 Dec 9;:]. *Pediatr Nephrol.* 2021;36(4):889-898. doi:10.1007/s00467-020-04774-2
4. Sawai T, Nangaku M, Ashida A, et al. Diagnostic criteria for atypical hemolytic uremic syndrome proposed by the Joint Committee of the Japanese Society of Nephrology and the Japan Pediatric Society. *Pediatr Int.* 2014;56(1):1-5. doi:10.1111/ped.12274
5. Loirat C, Fakhouri F, Ariceta G, et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. *Pediatr Nephrol.* 2016;31(1):15-39. doi:10.1007/s00467-015-3076-8
6. Pugh D, O'Sullivan ED, Duthie FA, Masson P, Kavanagh D. Interventions for atypical haemolytic uraemic syndrome. *Cochrane Database Syst Rev.* 2021;3(3):CD012862. Published 2021 Mar 23. doi:10.1002/14651858.CD012862.pub2
7. Parker CJ. Update on the diagnosis and management of paroxysmal nocturnal hemoglobinuria. *Hematology Am Soc Hematol Educ Program.* 2016;2016(1):208-216. doi:10.1182/asheducation-2016.1.208
8. Patriquin CJ, Kiss T, Caplan S, et al. How we treat paroxysmal nocturnal hemoglobinuria: A consensus statement of the Canadian PNH Network and review of the national registry. *Eur J Haematol.* 2019;102(1):36-52. doi:10.1111/ejh.13176

9. Devos T, Meers S, Boeckx N, et al. Diagnosis and management of PNH: Review and recommendations from a Belgian expert panel. *Eur J Haematol.* 2018;101(6):737-749. doi:10.1111/ejh.13166
10. Lee JW, Sicre de Fontbrune F, Wong Lee Lee L, et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. *Blood.* 2019;133(6):530-539. doi:10.1182/blood-2018-09-876136
11. Kulasekararaj AG, Hill A, Rottinghaus ST, et al. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. *Blood.* 2019;133(6):540-549. doi:10.1182/blood-2018-09-876805

APPENDIX:

Table 1: ULTOMIRIS Weight-Based Dosing Regimen - PNH and aHUS

Body Weight Range (kg)	Loading Dose (mg)	Maintenance Dose (mg) and Dosing Interval	
5 to less than 10	600	300	Every 4 weeks
10 to less than 20	600	600	
20 to less than 30	900	2,100	Every 8 weeks
30 to less than 40	1,200	2,700	
40 to less than 60	2,400	3,000	
60 to less than 100	2,700	3,300	
100 or greater	3,000	3,600	

Effective date: 01/01/2022

Revised date: 06/03/2021